1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsMultiple Sclerosis Research Program (MSRP) Clinical Trial Award (CTA) is sponsored by Defense Health Agency Contracting Activity - DHACA (Department of Defense). This award supports the rapid implementation of clinical trials with the potential to significantly impact the treatment or management of multiple sclerosis.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - DoW Multiple Sclerosis Clinical Trial Award DoW Multiple Sclerosis Clinical Trial Award Agency: Defense Health Agency Contracting Activity - DHACA Assistance Listings: 12. 420 -- Military Medical Research and Development Last Updated: May 13, 2026 View version history on Grants.
gov Summary: The fiscal year 2026 (FY26) Multiple Sclerosis Research Program (MSRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of multiple sclerosis. All applications must address at least one of the FY26 MSRP CTA focus areas.
Clinical trials may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies. Distinctive Features: The FY26 CTA offers two funding levels.
The following are generalized descriptions of the scope of research appropriate for each funding level: • Funding Level 1 (CTA-FL1) supports small-scale, proof-of-principle clinical trials (e.g., pilot, first-in-human, phase 0) to demonstrate feasibility or inform the design of more advanced trials, or other clinical trials that are appropriate for this funding level.
Preliminary data relevant to the proposed clinical trial are required. • Funding Level 2 (CTA-FL2) supports larger-scale clinical trials at phase 1 or phase 2 that seek to show preliminary evidence of safety or efficacy (i.e., benefit of clinical or paraclinical outcomes) in relevant patient populations.
Clear description and justification should be provided, which could include, but is not limited to, the intervention type, trial duration, sample size, outcome measures, assessment tools and frequency of assessment. Preliminary data relevant to the proposed clinical trial in MS populations are required.
For the purposes of this funding opportunity, Regulatory Agency refers to the U.S. Food and Drug Administration (FDA) or any relevant international regulatory agency unless otherwise noted. Grantor contact information File name Description Last updated HT942526MSRPCTA_GG.
pdf FY26 MSRP CTA Program Announcement Link to additional information Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity : Science technology and other research and development Your account requires additional identity verification.
According to the current listing, eligibility includes: Applicants must address at least one of the FY26 MSRP CTA focus areas. Clinical trials may evaluate promising new products, pharmacologic agents, devices, clinical guidance, and/or emerging approaches and technologies. Confirm the full requirements in the official notice before applying.
The current listing shows $4,000,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Multiple Sclerosis Research Program (MSRP) Clinical Trial Award (CTA) is funded by Defense Health Agency Contracting Activity - DHACA (Department of Defense). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
CDMRP's FY26 portfolio funds 34 programs, and October 2026 is dense with full-application deadlines: PRCRP October 5, PCRP October 7, MRP October 14. Every one of them is gated behind a pre-application that closed months earlier. Here is what that two-step structure actually costs applicants, and how to be inside the gate for FY27.
Read articleThe Department's FY26 SBIR/STTR Release 3 opened June 24 with roughly 37 topics across DARPA, the Navy, the Air Force, and the defense components, all closing July 22. The compressed four-week window is unforgiving, but the bigger mistake founders make is treating every component the same. Here is how to read the release, the eligibility rules that disqualify good companies, and why the component you target matters more than the topic you pick.
Read articleDoW's 2026 SBIR Broad Agency Announcement now operates on a monthly pre-release / quarterly close cadence. The 42 topics closing June 24 are the first test of whether the new rhythm produces the steady-state deal flow defense innovators have been asking for since 2022.
Read article